About the Authors
- Michael Erb
-
Affiliation Santhera Pharmaceuticals, Liestal, Switzerland
- Barbara Hoffmann-Enger
-
Affiliation Santhera Pharmaceuticals, Liestal, Switzerland
- Holger Deppe
-
Affiliation Santhera Pharmaceuticals, Liestal, Switzerland
- Michael Soeberdt
-
Affiliation Santhera Pharmaceuticals, Liestal, Switzerland
- Roman H. Haefeli
-
Affiliations Santhera Pharmaceuticals, Liestal, Switzerland, Biozentrum, University of Basel, Basel, Switzerland
- Christian Rummey
-
Affiliation Santhera Pharmaceuticals, Liestal, Switzerland
- Achim Feurer
-
Affiliation Santhera Pharmaceuticals, Liestal, Switzerland
- Nuri Gueven
-
* E-mail: nuri.gueven@santhera.com
Affiliation Santhera Pharmaceuticals, Liestal, Switzerland
Competing Interests
The authors have read the journal's policy and have the following conflicts: During the preparation of this manuscript, all authors were paid employees of Santhera Pharmaceuticals (Switzerland). Santhera is marketing Catena® (Idebenone) for the treatment of Friedreich's Ataxia in Canada and develops Catena for several other mitochondrial and neuromuscular indications. Compounds # 1, 3–5, 7, 9–14, 16–35, 53–57, 60–71 are subject of two international patent applications (WO/2012/022467 and WO/2012/022468). This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: ME NG. Performed the experiments: ME RHH. Analyzed the data: ME CR NG. Contributed reagents/materials/analysis tools: BH HD MS AF. Wrote the paper: AF NG. Contributed reagents, designed and synthesized compounds: BH HD MS AF.